Ads
related to: lilly diabetes- How To Screen For T1D
Learn How To Screen
Patients For T1D
- Learn About T1D Treatment
Discover T1D Treatment for
Appropriate Patients
- Familial Risk
Discover T1D Familial Risks
For Patients
- Patient Support
Discover Support For Patients
On Their T1D Journey
- How To Screen For T1D
Search results
Prediction: These Could Be the Best-Performing Pharmaceutical Stocks Through 2030
The Motley Fool via AOL· 4 days agoMeanwhile, Eli Lilly's diabetes portfolio is nearly as strong as Novo Nordisk's. That said, the latter is also seeking to diversify its pipeline. It is ...
Why Is Lilly (LLY) Up 4.5% Since Last Earnings Report?
Zacks via Yahoo Finance· 7 days agoHowever, supply constraints, given significant demand, hurt sales. From the second half of 2024, ...
This Is the Biggest Risk for Eli Lilly and Novo Nordisk Investors | The Motley Fool
The Motley Fool· 5 days agoEli Lilly (LLY 0.65%) and Novo Nordisk (NVO 1.87%) are the two most valuable healthcare companies in...
Britain poised to offer Eli Lilly's weight-loss drug to patients - Indianapolis Business Journal
Indianapolis Business Journal· 2 days agoEli Lilly and Co.’s Mounjaro is being recommended for weight loss for some United Kingdom patients...
Aristocrats in Disguise: 3 Blue-Chip Stocks With Stealth Growth Potential
InvestorPlace via Yahoo Finance· 6 days agoAlthough there is no hard-and-fast rule about what constitutes a blue-chip stock, they all tend to...
Eli Lilly and Company (NYSE:LLY) Major Shareholder Lilly Endowment Inc Sells 22,206 Shares of Stock
ETF DAILY NEWS· 2 days agoEli Lilly and Company (NYSE:LLY – Get Free Report) major shareholder Lilly Endowment Inc sold 22,206 shares of the business’s stock in a transaction that ...
Britain considers offering Lilly weight-loss drug on better terms than Wegovy
Reuters· 2 days agoIn its draft roadmap for Mounjaro, known chemically as tirzepatide and sold in the U.S. for weight...
...Loss Drug Market To Rocket To $130B By 2030 With Eli Lilly, Novo Nordisk In Lead: Goldman Sachs -...
Benzinga· 7 days agoGoldman Sachs analysts re-rated Eli Lilly And Co LLY and Novo Nordisk A/S NVO, citing the potential...
What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences...
Benzinga· 14 hours agoAt the EASL International Liver Congress 2024, Eli Lilly And Co LLY shared an abstract highlighting fibrosis results from a Phase 2 trial of tirzepatide in patients with metabolic ...
Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors...
The Woonsocket Call· 5 days agoEli Lilly and Company (NYSE: LLY) today announced updated data from the Phase 1/2 clinical trial evaluating olomorasib as a monotherapy in patients with KRAS G12C-mutant advanced ...